Procop, M.de), a member of the
editorial board of Drug Discovery Today, Proteomics, Molecular Biotechnology
and Expert Review of Proteomics . The words "believe," "expect," "intend,"
"estimate," "anticipate," "will," "could," "should" and similar expressions
are intended to further identify such forward-looking statements for purposes
of the Private Securities Litigation Reform Act of 1995.591.com

science microbiology

Prior to joining
LINCO Diagnostic Services in 2003, Dr. is currently a Professor of Pathology at
Virginia Commonwealth University and director of the Molecular Diagnostics
Laboratory at Virginia Commonwealth University Health System . Luminex's xMAP
technology received the 2005 Clinical Diagnostics Technology of the Year Award
from Frost + Sullivan. From 1978-1989 Dr.

Business Editors/Health/Medical Writers

OCEANSIDE , Calif.

anatomy mammal

"
The Chairman of the Luminex Scientific Advisory Board is James W. Jacobson, Ph. degree in 1986
from Washington University in Saint Louis, Missouri and B.A. degrees in Biochemistry
from the Indiana University School of Medicine in 1981 and 1986, respectively.

Andrea Ferreira -Gonzalez, Ph. Joos is a world leading expert and opinion
leader within the field of protein microarray technology. Procop joined the Cleveland Clinic in 1998 where
he currently serves as Section Head , Clinical Microbiology.
Factors that could cause Luminex's actual results or performance to differ
materially include risks and uncertainties relating to, among others, market
demand and acceptance of Luminex's products, the Company's dependence on
strategic partners for development, commercialization and distribution of
products, fluctuations in quarterly results due to a lengthy and unpredictable
sales cycle, Luminex's ability to scale manufacturing operations, potential
shortages of components , competition, the timing of regulatory approvals and
any modification of the Company's operating plan in response to its ongoing
evaluation of its business, as well as the risks discussed under the heading
"Risk Factors" in Luminex's Annual Report on Form 10-K for the year ended
December 31, 2004, as filed with the Securities and Exchange Commission.com

Luminex Media Contact:
Sandra G.
Dr.
Live Webcast/Replay: www.

biophysics eukaryotic

AUSTIN, Texas, Luminex Corporation
(Nasdaq: LMNX), a leading multiplex solution developer, announced today the
formation of a new Scientific Advisory Board.
Following post-doctoral work at North Carolina State University and Duke
University, he was a faculty member in the Department of Biology, University
of Houston, Houston , Texas.S. Thomas Caskey, M. Caskey has received numerous academic and industry-related honors.D.biochipnet . It is important to
note that the Company's actual results or performance could differ materially
from those anticipated or projected in such forward-looking statements.

Dr. The webcast will be archived and available on SeraCare's
web site for 30 days.

anatomy genetics

P. Bowsher retired after 30 years at the
Lilly Research Laboratories. and Ph. Dr. Dr. Cramer to our scientific advisory team adds
significant experience in public health and administration. During the same period he has also acted as the Director
of Research at the Department of Cardiothoracic Surgery.invrel. Forward-looking statements involve
known and unknown risks and uncertainties, which may cause a company's
actual results, performance and achievement in the future to differ
materially from forecasted results, performance, and achievement . We undertake no obligation and do not intend to revise or
update publicly any forward looking statements for any reason.

biology science

; Andrea Ferreira-Gonzalez, Ph. and M. His
experience in writing and receiving government grants will aid the
Company as we continue to market our technology to both the private
and public sectors," says Jacques Tizabi, UDTT's chairman and CEO. Cramer's expertise to
evaluate the feasibility of new research projects and to monitor and
apply for relevant government grants for existing and new research,
development, and commercialization undertakings. From 1998 to 2003 he has been a research professor at the
departments of Cardiothoracic Surgery and Molecular Microbiology and
Immunology .

physiology sciences

D.D.D.D. Dr.
Dr. Dr.

Universal Detection Technology Announces Appointment of Dr. Donald V. Cramer to Its Scientific Advisory Board

M. Cramer has years of professional experience
including academic and administrative responsibilities with various
public and private organizations.

mammal anatomy

From
1994 to 1998, Dr. Bowsher received his B. Procop was Pathology Resident at Duke University
Medical Center and Medical Microbiology Fellow at Mayo Clinic and thus holds
extensive experience within both clinical microbiology and pathology from
major US hospitals. The
forward-looking statements contained herein represent the judgment of Luminex
as of the date of this press release, and Luminex expressly disclaims any
intent, obligation or undertaking to release publicly any updates or revisions
to any forward -looking statements to reflect any change in Luminex's
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statements are based. Cramer to its scientific advisory board.
These risks and uncertainties include, among other things, the funding
of amounts of capital adequate to provide for our working capital
needs and our timely repayment of debt, our ability to timely and cost
effectively complete the development and testing of our products
targeted to the bio-chemical market, our ability to commercially
produce our products on a profitable basis , commercial acceptance of
our products, product price volatility, product demand, market
competition and general economic conditions, and other factors
described in the Company's filings with the Securities and Exchange
Commission.

sciences immunology

Dr.D. Dr.: Dr. Further information on Luminex Corporation or xMAP can
be obtained on the Internet at http://www.

Donald V.D.com (select "Investor
Relations"). For more information please visit
www.

medical top

D., is Director and Chief Executive
Officer-Elect and Chief Operating Officer of the Brown Foundation
Institute of Molecular Medicine for the Prevention of Human Diseases
(IMM), at the University of Texas Health Science Center at Houston. She served as a member of Clinical
Laboratory Improvement Advisory Committee (CLIAC) to HHS.219. Cramer will
help shape and maintain a focused research and development strategy
for the company and will provide a wealth of expertise in seeking
government and private grants and awards for future and present
research projects.
"The addition of Dr.com

Except for historical information contained herein, the statements
in this news release are forward-looking statements that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.

mammal physiology

Patrick J.; and Gary W. Dr. Ferreira-
Gonzalez has been recognized both nationally and internationally for her work
in the field of molecular diagnostics. is head of the Biochemistry Department of the NMI
Natural and Medical Sciences Institute at the University of Tubingen. Procop, M. The Company's xMAP(R) system is an open-architecture, multi-analyte
technology platform that delivers fast, accurate and cost -effective bioassay
results to markets as diverse as pharmaceutical drug discovery, clinical
diagnostics and biomedical research, including the genomics and proteomics
research markets. The Company's xMAP technology is sold worldwide and is
already in use in leading research laboratories as well as major
pharmaceutical, diagnostic and biotechnology companies.udetection.

About SeraCare Life Sciences

SeraCare Life Sciences, Inc. The Company's
offerings include plasma-based therapeutic products , diagnostic
products and reagents, cell culture products, specialty plasmas, in
vitro stabilizers , and the Global Repository(R), comprised of clinical
samples (DNA, RNA, tissue, and serum) for the application of human
genetics to target validation for drug discovery.com and
www.

science histology

is Vice President , Research + Development of
Luminex Corporation. Jacobson was Laboratory Director at Cytastar Laboratories ,
Virus Reference Laboratories and SpectraCell Laboratories in Houston, Texas. Ferreira-Gonzalez completed her
Ph.D.
Donald V.bbii.

sciences anatomy

, Luminex Vice President, Research + Development.

Ronald Bowsher , Ph. is a partner in the data analysis and statistical
consulting company, Bowsher Brunelle Smith , LLC and a Fellow of the American
Association of Pharmaceutical Sciences.

Statements made in this release that express Luminex's or management's
intentions, plans, beliefs, expectations or predictions of future events are
forward-looking statements.1508
soakpr@earthlink.seracare .

embryology basic

; Ronald Bowsher, Ph.D. UDTT, in cooperation with NASA's Jet Propulsion Laboratory
(JPL), has developed a bio-terror `smoke' detector, which combines
JPL's spore detection technology with UDTT's aerosol capture device.
Telephone: Numbers are 800/ 779-2934 or 646/ 862-1143 for
international callers .

medicine immunology

Balthrop, president and chief executive officer of
Luminex Corporation, commented, "The establishment of our new Scientific
Advisory Board with world-class scientists and physicians is another milestone
in extending Luminex's leadership position as a scientific innovator.D.
Dr. Bowsher also serves as the Chief Scientific Officer at LINCO Diagnostic
Services, and has published extensively on the development and validation of
ligand binding assays for determination of biotechnology products and novel
biomarkers and is the 2006 past Chairman of the AAPS Biotechnology Section.D. Dr.net

Business Editors/Technology Writers/Defense Writers

LOS ANGELES----Universal Detection
Technology (OTCBB:UDTT) today announced that it has appointed Dr. Cramer served as the Associate Professor
of Pathology (with Tenure) at University of Pittsburgh School of
Medicine.getdna.

neurobiology developmental

A brief summary of accomplishments of the Luminex Scientific Advisory
Board members appears below.

C. located in St. Joos
is a scientific advisor of BioChipNet (http://www.luminexcorp . Cramer
has been a consultant to the Department of Abdominal Organ
Transplantation from 2003 to present. (NASDAQ: SRLS), an innovative developer and provider of
human and animal based diagnostic , therapeutic and research products
for the life science industry, announced today that it will release
its fiscal 2005 first quarter results after the market closes on
Wednesday, February 9, 2005, and will then host a conference call and
simultaneous webcast at 4:30 p. Both the call and webcast are
open to the general public.

biology science

Caskey earned his medical
degree from Duke University School of Medicine and his undergraduate degree

from the University of South Carolina. Joos is an invited speaker, advisor
and chairman at major international biochip conferences.
The company is planning to utilize Dr. Donald V. Cramer's major areas of research interest and experience
include Pathology , Immunology, Genetics, and Transplantation Biology. Management believes that the Company's technology ,
together with third party technologies and devices, has positioned it
to capitalize on growth and value opportunities related to Homeland
Security.----SeraCare Life
Sciences, Inc.m. is a manufacturer and provider of
biological products and services for diagnostic, therapeutic, drug
discovery, and research organizations worldwide.

medicine specialties

Thomas Caskey, M.;
Thomas Joos, Ph.

James W.

He is a member of the National Academy of Sciences and the Institute of
Medicine. in Molecular Biology at the George Washington University in Washington
DC.D. In addition to serving as the Section Head and Clinical
Microbiology Laboratory Director, he also serves as Anatomic Pathologist,
specializing in Infectious Diseases Pathology. Currie
Vice President, Finance
Chief Financial Officer
Luminex Corporation
512. Oak
Nsight Public Relations
321. His
other employment activities include membership at the National
Institutes of Health reviewer reserve, National Center for Research
Resources.
He has received several grants and fellowships from the National
Institutes of Health, American Cancer Society, BRSG Research Support,
Sterling Drug Company, American Heart Association, United Liver
Association, the Du Pont and Merck Pharmaceutical Company, and many
other organizations. EST. A replay of the call will be available for 4
days at 800/ 633-8284 or 402/ 977 -9140 (Reservation # 21231887).

health animal

degrees
from Utah State University in 1980 and 1982,
respectively .D., F. He is Board certified in Internal
Medicine, Clinical Genetics, Metabolic Diseases and Molecular Diagnostics.

Thomas Joos, Ph. Dr. Cramer, D.

SeraCare to Host First Quarter 2005 Conference Call and Webcast Wednesday February 9 at 4:30 PM EST

SeraCare is publicly traded on the NASDAQ national stock market
under the symbol SRLS.

embryology biology

C. Dr. He is a member of the scientific advisory
board of the "Plasma Proteome Institute" Washington, DC, USA and of the SAB of
Epitome Biosystems, Waltham , MA, USA.

About Luminex:
Luminex Corporation develops, manufactures and markets proprietary
biological testing technologies with applications throughout the life sciences
industry.com.8020
hcurrie@luminexcorp. He served as the Acting Director of
Surgical Research and the Director of Transplantation Biology at the
Cedars-Sinai Medical Center in Los Angeles from 1989 to 1992. Dr .

developmental health

D. He has served as president of American Society of Human
Genetics, the Human Genome Organization and The Academy of Medicine,
Engineering and Science of Texas (TAMEST). Charles, Missouri. He has published
numerous papers, including recent articles in Drug Discovery Today, Proteomics
and Trends in Biotechnology. Procop earned his medical degree from
Marshall University School of Medicine and his undergraduate degree from
Eastern Michigan University.

Luminex Corporate Contact:
Harriss T. SeraCare is
headquartered in Oceanside, CA, and maintains facilities in Cambridge
and West Bridgewater, MA; Frederick and Gaithersburg, MD; and Hatboro,
PA.

medical eukaryotic

Board Members include renowned experts in molecular diagnostics, bioanalytical
research and protein microarray technology.
Jacobson, Ph. in Chemistry in
1977 from Indiana University and his M.S.net or
http: //www.

mammal medical

Comprised of world-renowned
physicians and scientists, the Luminex Scientific Advisory Board will play an
important role of guidance and participation in Luminex's research and
development programs. Jacobson joined Luminex Corporation in May 1998. Jacobson received his Ph.S. Dr. She has been
involved in the development of clinical guidelines with the Clinical and
Laboratory Standards Institute and currently serves as advisor to the FDA-
Molecular Genetics Advisory Panel.

Gary W.V., Ph.

developmental microbiology

Luminex Corporation Announces Formation of New Scientific Advisory Board

The
unique expertise of these thought leaders will contribute to our strategic
growth and provide a further impetus to our development of leading-edge
products and services that support our xMAP(R) technology across multiple
biotechnology and life sciences markets. The other
five founding members of the Luminex Scientific Advisory Board members are C.D.S. He is also Vice-President at LINCO
Diagnostic Services, Inc. He is an Associate Professor of
Pathology at the Cleveland Clinic Lerner College of Medicine of Case Western
Reserve. On the forefront with implementation of molecular diagnostic tests in
the clinical settings, he is an opinion leader representing the new generation
of healthcare professionals.

top sciences

She has served in various capacities for
the Association for Molecular Pathology where she was a member of the Clinical
Practice Committee, chair of the Professional Relations Committee and more
recently she was elected AMP president. Prior to his
current positions, Dr.

About Universal Detection Technology

Universal Detection Technology (UDTT), founded in 1973, is a
developer of monitoring technologies, including bio-terrorism
detection devices.
For more information, please visit http://udtt.

medicine sciences

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)